VNRX News

VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

Volition Announces Data to Support Use of Nu.Q® NETs in New Indication

Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

VolitionRx Secures $2.0 Million in Funding

VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats

Volition Issues Business Review 2025

Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer

VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis USA - English France - Français

VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use USA - English France - Français